Trial reportAllergy2023
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
Trial report in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- A meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle.Frontiers in immunology · 2025Pooled it
- Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Non-Invasive Scalp Tape-Strip RNA Sequencing Captures Disease Activity and Treatment-Response Signatures in Alopecia Areata.Allergy · 2026Article
- Improvement of Mixed Inflammatory Environment in Nasal Secretions of Diffuse Type 2 Chronic Rhinosinusitis With Nasal Polyps Under Dupilumab.Clinical and translational allergy · 2026Article
- Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases.Molecular psychiatry · 2026Article
- Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE.Frontiers in immunology · 2026Article
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.Journal of inflammation research · 2026Review
- Alopecia areata.Nature reviews. Disease primers · 2025Review
- Meta-Analysis of Gene Expression Reveals the Core Transcriptomic Profile of Lesional Scalp in Alopecia Areata.Dermatology and therapy · 2025Review
- The AhR pathway is dysregulated in alopecia areata.Journal of translational autoimmunity · 2025Article
- Article
- Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Case Report: Severe ophiasis-pattern alopecia areata with concomitant atopic dermatitis in a 5-year-old boy successfully treated with dupilumab.Frontiers in pediatrics · 2025Article
- Correlation between increased total serum IgE levels and clinical features in alopecia areata patients.Frontiers in immunology · 2025Article
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.Frontiers in immunology · 2025Review
- Keloid development among patients with alopecia areata: a multicenter retrospective study.Archives of dermatological research · 2024Article
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata.American journal of clinical dermatology · 2024Review
- Interleukin-33 links asthma to alopecia areata: Mendelian randomization and mediation analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study.Archives of dermatological research · 2024Observational
- Genetic association between asthma and alopecia areata: A two-sample Mendelian randomization study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway.
methodsWe evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open-label dupilumab for 24 weeks. Changes in biomarker levels were measured at weeks 12, 24, and 48 and were also correlated with clinical hair regrowth.
resultsAt week 24, preceding clinical hair regrowth outcomes, only dupilumab-treated patients presented significant suppression of cellular infiltrates, and multiple Th2-related, markers (CCL13/MCP-4, CCL18/PARC, CCL26/eotaxin-3, CCL24/Eotaxin-2), coupled with significant upregulation in the hair keratins. Th1-related suppression was evident later (week 48) when all patients received open-label dupilumab. Results were more pronounced in atopic AA patients, that showed 48% and 97% improvements in the lesional AA scalp profile at weeks 24 and 48, respectively, while 2% worsening was seen in the placebo arm at week 24. Moreover, placebo-treated patients presented 54% worsening in hair keratins when compared with baseline at week 24. At week 24, increases in hair keratins showed significant correlations only with decreases in Th2-related markers.
conclusionsScalp biomarkers provide evidence of dupilumab efficacy in AA, detected even prior to clinical response, with exclusive correlations between early suppression of Th2 markers and increased hair keratins. These findings strengthen previous reports suggesting a possible role for Th2 cytokines as AA drivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.